Novel therapeutic approaches for the management of hepatitis infections

Ther Deliv. 2024 Mar;15(3):211-232. doi: 10.4155/tde-2023-0074. Epub 2024 Feb 27.

Abstract

Hepatitis B virus (HBV) & hepatitis C virus (HCV) infection is a substantial reason for morbidity and mortality around the world. Chronic hepatitis B (CHB) infection is connected with an enhanced risk of liver cirrhosis, liver decompensation and hepatocellular carcinoma (HCC). Conventional therapy do face certain challenges, for example, poor tolerability and the growth of active resistance. Thus, novel treatment procedures are essential to accomplish the initiation of strong and stable antiviral immune reactions of the individuals. This review explores the current nanotechnology-based carriers for drug and vaccine delivery to treat HBV and HCV.

Keywords: Hepatitis B virus; anti-viral therapy; drug delivery; nanotechnology; vaccine delivery.

Plain language summary

Hepatitis infections are a major health problem that affects lots of people across the globe. Without treatment, it can seriously harm the liver and might even lead to a type of liver cancer. The treatments we currently have can sometimes cause side effects or the virus can learn how to fight back against them. This means we need new and better ways to treat it. In our article, we talk about how Hepatitis B and C affects the body and how our natural defenses try to protect us. We then dive into a kind of science called nanotechnology, which uses tiny particles to help deliver medicine or vaccines in a better way. This new method could help medications be better at treating Hepatitis B and C.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular*
  • Hepatitis B* / drug therapy
  • Hepatitis B* / prevention & control
  • Hepatitis B, Chronic* / drug therapy
  • Hepatitis C* / drug therapy
  • Humans
  • Liver Neoplasms*

Substances

  • Antiviral Agents